 serum patients polymyalgia rheumatica giant cell arteritis Polymyalgia rheumatica giant cell arteritis diseases brisk acute phase response Cytokines release acute phase proteins hepatocytes sensitive bioassay hybridoma growth factor properties levels sequential sera untreated patients PMR/GCA activity untreated patients significant decline levels successful steroid therapy patients serum levels months initiation treatment endothelial cells potent source persistence circulation evidence disease activity explicable normalization acute phase response commencement steroid therapy circulating levels high steroids additional effects hepatocyte function